États-Unis · Plateformes & données · MarketBeat

Ocugen Eyes 2027 Trial Results and FDA Filing for Lead Gene Therapy

Publié par MarketBeat · États-Unis il y a 1 h

Image from MarketBeat Media, LLC. · MarketBeat

Résumé détaillé

Ocugen (NASDAQ:OCGN) expects pivotal data for its lead experimental gene therapy for retinitis pigmentosa in the first quarter of 2027, a milestone that could set up a regulatory filing later that year, CEO Shankar Musunuri said at a company presentation. The company is also advancing treatments fo

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

Ocugen Eyes 2027 Trial Results and FDA Filing for Lead Gene Therapy

Résumé détaillé

À lire aussi

Nvidia CEO Jensen Huang Says AI's 'Most Profound Impact' Will Be in Life Sciences -- and Eli Lilly Is Already Building on It

I inherited $1.4 million from my father. Am I wrong to ask my husband of 25 years for a postnuptial agreement?

Oil prices rise after Trump says no Iran deal needed: 'We've got their Strait'

Grupo Equatorial Q3 2026 slides: EBITDA rises amid debt pressures

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Palo Alto Networks CEO has a blunt warning before earnings

Ocugen Eyes 2027 Trial Results and FDA Filing for Lead Gene Therapy

Résumé détaillé

Partager

À lire aussi

Nvidia CEO Jensen Huang Says AI's 'Most Profound Impact' Will Be in Life Sciences -- and Eli Lilly Is Already Building on It

I inherited $1.4 million from my father. Am I wrong to ask my husband of 25 years for a postnuptial agreement?

Oil prices rise after Trump says no Iran deal needed: 'We've got their Strait'

Grupo Equatorial Q3 2026 slides: EBITDA rises amid debt pressures

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Palo Alto Networks CEO has a blunt warning before earnings